trending Market Intelligence /marketintelligence/en/news-insights/trending/9o5bdjw2-pofugmbjb8jkq2 content esgSubNav
In This List

Regenxbio appoints director

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Regenxbio appoints director

Regenxbio Inc. appointed Alexandra Glucksmann as a director, effective May 25.

Glucksmann is currently the president and CEO of Cedilla Therapeutics Inc.

Rockville, Md.-based REGENXBIO, is a clinical-stage biotechnology company, which provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease.